ArticleScientific reports2026
Porphyromonas gingivalis promotes oral squamous cell carcinoma progression via the IL-6/EZH2/Snai2 axis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Oral squamous cell carcinoma (OSCC) is a common malignancy with poor prognosis. Chronic infection with Porphyromonas gingivalis (P.g.) has been implicated in OSCC progression, but the molecular mechanisms underlying P.g.-induced tumor invasion and metastasis remain incompletely understood. ELISA, flow cytometry, proliferation assay and migration assay, were conducted on OSCC primary cells and the HSC-2 cell line under P.g. infection or IL-6 stimulation. Zeste homologue 2 (EZH2) and Snai2 were modulated via overexpression, knockdown, and inhibitor treatments, to evaluate the role of EZH2 and Snai2 in the regulation of OSCC phenotypes. The relationships between Snai2 and epithelial-mesenchymal transition (EMT) was analyzed using GSEA, differential expression, and KEGG pathway enrichment. For in vitro assay, P.g. infection significantly increased IL-6 levels in the oral microenvironment. IL-6 upregulation promoted OSCC cell proliferation and migration by enhancing EZH2 and Snai2 expression. EZH2 overexpression increased Snai2 transcription and OSCC malignancy, whereas EZH2 siRNA/inhibitor or Snai2 siRNA attenuated these effects. In bioinformatic analysis results, DEG and survival analysis showed the higher expression of Snai2 in OSCC patientsꞌ group and the negative relevance of survival probability with Snai2 expression, respectively. KEGG enrichment and PPI analysis indicated the relationships among EZH2 or Snai2 expression, EMT and infection-related signaling pathways. Our study revealed a novel IL-6/EZH2/Snai2 signaling axis, which connected the P.g. infection, IL-6 upregulation, abnormal expression of EZH2 and Snai2, and OSCC progression. This study filled the gap of molecular mechanisms underlying P.g.-induced OSCC invasion and metastasis, providing a potential therapeutic target for inhibiting OSCC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.